Skip to main contentAI and Advanced
/
HIKAL · NSEMarket ticker unavailable · configure an authorised index feed
HI
NSE · Equity shares · Biotechnology & Drugs13.30 · 6.29%
Hikal HIKAL
NSE:INR 224.8
BSE:INR 215
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for HIKAL
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 211.5
Day rangeINR 203.83 — INR 226
52-week rangeINR 146.25 — INR 282.7
Volume18.17 L
Market cap2,687.95
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,712.6
Net Income (INR Cr)-48.8
Rev Growth (5 Year %)-0.09
Book Value96.76
EPS0.53
Price/BV2.32Computed
Research path: Interpret Hikal's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
HIKALHikal1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,365.4 | 2,528.9 | 2,487.15 |
| Cash Equivalents | 13.8 | 0.1 | 0.43 |
| Other Liabilities Total | 107.6 | 75 | 87.34 |
| Long Term Debt | 373.1 | 367.2 | 422.85 |
| Common Stock Total | 24.7 | 24.7 | 24.66 |
| Other Current Assets Total | 38.5 | 0.2 | 5.7 |
| Total Assets | 2,365.4 | 2,528.9 | 2,487.15 |
| Current Portof LT Debt/Capital Leases | 308 | 131.8 | 103.54 |
| Total Equity | 1,198.8 | 1,262.3 | 1,187.66 |
| Long Term Investments | 30.8 | 10.3 | 5.89 |
| Retained Earnings(Accumulated Deficit) | 1,174.1 | 1,199.7 | 1,125.07 |
| Total Common Shares Outstanding | 12.33 | 12.33 | 12.33 |
| Tangible Book Valueper Share Common Eq | 96.76 | 101.74 | 95.5 |
| Total Liabilities | 1,166.6 | 1,266.6 | 1,299.49 |
| Total Debt | 683.8 | 764.7 | 817.58 |
| Short Term Investments | 31.8 | 4.8 | 7.97 |
| Cashand Short Term Investments | 45.6 | 17.8 | 20.67 |
| Total Receivables Net | 441.9 | 616 | 606.62 |
| Deferred Income Tax | 4.3 | 32.5 | 30.04 |
| Accounts Receivable-Trade Net | 441.6 | 523.5 | 557.86 |
| Property/Plant/Equipment Total-Net | 1,421.6 | 1,477.9 | 1,474.82 |
| Total Current Liabilities | 678.9 | 789.5 | 756.63 |
| Total Inventory | 358.1 | 344.6 | 320.04 |
| Accounts Payable | 266.5 | 304.1 | 278.85 |
| Other Currentliabilities Total | 104.4 | 79.7 | 70.67 |
| Total Long Term Debt | 375.8 | 369.6 | 425.48 |
| Intangibles Net | 5.8 | 7.8 | 10.15 |
| Other Long Term Assets Total | 15.4 | 24.3 | 18.21 |
| Note Receivable-Long Term | 7.7 | 13.2 | 11.47 |
| Total Current Assets | 884.1 | 995.4 | 966.62 |
| Capital Lease Obligations | 2.7 | 2.4 | 2.63 |
| Accumulated Depreciation Total | Not available | -852.6 | -725.88 |
| Accrued Expenses | Not available | 10.6 | 15.02 |
| Other Equity Total | Not available | -0.2 | -0.19 |
| Prepaid Expenses | Not available | 16.8 | 13.58 |
| Additional Paid-In Capital | Not available | 38.1 | 38.12 |
| Cash | Not available | 12.9 | 12.27 |
| Property/Plant/Equipment Total-Gross | Not available | 2,209.3 | 1,786.36 |
| Notes Payable/Short Term Debt | Not available | 263.3 | 288.56 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %2.3
Margins
Operating Margin 12m-1.66
Operating Margin 5y Avg7.61
Net Profit Margin 12m-2.85
Net Profit Margin 5y3.76
Yield
Dividend Yield %0.27
Valuation
Price to Sale Ratio1.57
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk51.39
Analyst consensus
ConsensusStrong Buy
Consensus score1.00
Analyst opinions1
Strong Sell count0
Sell count0
Hold count0
Buy count0
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,936.55 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,380.2 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,982.4 | 1.69 L | 72.73 | — |
| Cipla | INR 1,406.1 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,118.3 | 1.11 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 68.85%
- FII
- 0.98%
- MF
- 5.92%
- Other
- 24.25%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Hikal Ltd Technical Momentum Shifts Signal Mild Bullish Outlook Amid Mixed Indicators - MarketsMojoMarket news · 22 Jul 2026, 8:00 am
Hikal Ltd Technical Momentum Shifts Signal Mild Bullish Outlook Amid Mixed Indicators MarketsMojo
Hikal Ltd is Rated Hold by MarketsMOJO - MarketsMojoMarket news · 20 Jul 2026, 1:37 am
Hikal Ltd is Rated Hold by MarketsMOJO MarketsMojo
ET Now lists four stocks with up to 28% upside - MSNMarket news · 18 Jul 2026, 8:09 pm
ET Now lists four stocks with up to 28% upside MSN
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analysts - The Economic TimesMarket news · 16 Jul 2026, 11:17 pm
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analysts The Economic Times
Chemical Stock Quietly Diversifying into Animal Health and CDMO to Keep on Your Radar - Trade BrainsMarket news · 14 Jul 2026, 10:00 pm
Chemical Stock Quietly Diversifying into Animal Health and CDMO to Keep on Your Radar Trade Brains
Corporate actions
Events
- annual General MeetingPOM
- dividendRs.0.4000 per share(20%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- dividendRs.0.2000 per share(10%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- board Meetings(Revised)
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Hikal
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Hikal Limited is an India-based company, which is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. Its human health product categories include anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, and hemorheologic. Its animal health product categories include anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID. Its crop protection products are used in algaecide, biocide, fungicide, herbicide, insecticide, and intermediate. It offers contract research services for synthesis, process development, and manufacturing projects.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- HIKAL
- BSE Code
- 524735
Questions
Stock FAQ
What is the symbol and ISIN of Hikal?
Hikal has the symbol HIKAL and ISIN - INE475B01022.
What is the current price of Hikal?
Hikal is currently trading at INR 224.80.
What are the year high and year low of Hikal?
Hikal has a year high of INR 282.70 and a year low of INR 146.25.
What is the market capitalization of Hikal?
Hikal has a market capitalization of INR 2,687.95 crore.
What is the P/E ratio of Hikal?
Hikal has a P/E ratio of NA.
What is the dividend yield of Hikal?
Hikal has a dividend yield of 0.27%.
How is the financial performance of Hikal based on revenue, net income, and EPS?
Hikal has revenue of INR 1,712.60 crore, net income of INR -48.80 crore, and EPS of INR 0.54.
What is the book value of Hikal?
Hikal has a book value of INR 96.76.
What is the debt-to-equity ratio of Hikal?
Hikal has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Hikal?
Hikal has a price-to-book ratio of 2.32 and a price-to-sales ratio of 1.57.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.